This was confirmed by Dr. Eduardo Martinez, president of the Business Group of the Biotechnological and Pharmaceutical Industries of Cuba (BioCubaFarma), who said that work is being done on new generations of vaccines against the SARS-CoV-2 coronavirus that will allow more effectiveness to reduce transmission.
With the aim of advancing in the immunization strategy, the executive pointed out in an article published on Wednesday on Cubadebate web portal, that they will continue developing the Soberana 01 and Mambisa vaccine candidates to obtain their respective authorizations for use in emergencies.
The results are already being processed and we can say that they are positive and can justify such an approval to be used as booster doses, thus completing the authorization of all five vaccines, he pointed out.
“In the case of the Abdala, Soberana 02 and Soberana Plus vaccines, the information is being completed in order to submit the request for a definitive sanitary registration to the regulatory authority. The results support it and we think it could happen in a not too distant future,” he added.
We are also making progress in achieving recognition by the World Health Organization (WHO) of our vaccines.
The process for the authorization of Abdala began in March and the dossier is ready to be sent as soon as we are informed. In the case of Soberana 02 and Soberana Plus, the same document is being prepared and after it is ready, the Finlay Vaccines Institute will contact the WHO to start the process of international recognition, Martinez noted.
jg/arm/mgt/cdg
